 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Name:
|
MKC-231
|
|
Development Status:
|
investigational in U.S.
|
|
FDA Phase:
|
Inactive
|
|
Primary Medical Role:
|
May enhance the function of high-affinity choline uptake
system and acetylcholine release in the central nervous
system.
|
|
Role in Alzheimer's Disease:
|
Cholinergic signalling is sharply reduced early in the
course of AD, MKC-231 may increase the amount of choline
available to synthesize acetylcohline.
|
|
Contraindications:
|
n/a
|
|
Side Effects:
|
n/a
|
|
Companies:
|
Mitsubishi Tanabe Pharma
|
|
Notes:
|
MKC-231 development and testing in Alzheimer Disease has
been discontinued, in favor of being tested for Depression
and Anxiety disorders. This record last updated Dec 19, 2008.
|
Akaike A, Maeda T, Kaneko S, Tamura Y. Protective effect
of MKC-231, a novel high affinity choline uptake enhancer,
on glutamate cytotoxicity in cultured cortical neurons.
Jpn J Pharmacol. 1998 Feb;76(2):219-22.
Abstract
Bessho T, Takashina K, Tabata R, Ohshima C, Chaki H,
Yamabe H, Egawa M, Tobe A, Saito K. Effect of the novel
high affinity choline uptake enhancer 2-(2-oxopyrrolidin-1-
yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b] quinolin-
4-yl)acetoamide on deficits of water maze learning in rats.
Arzneimittelforschung. 1996 Apr;46(4):369-73.
Abstract
Murai S, Saito H, Abe E, Masuda Y, Odashima J, Itoh T.
MKC-231, a choline uptake enhancer, ameliorates working
memory deficits and decreased hippocampal acetylcholine
induced by ethylcholine aziridinium ion in mice.
J Neural Transm Gen Sect. 1994;98(1):1-13.
Abstract
|
|
|
|
|
Home
